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Abstract
Background: We know that patient care can be improved by implementing evidence-based innovations and
applying research findings linked to good practice. Successfully implementing innovations in complex
organisations, such as the UK’s National Health Service (NHS), is often challenging as multiple contextual dynamics
mediate the process. Research studies have explored the challenges of introducing innovations into healthcare
settings and have contributed to a better understanding of why potentially useful innovations are not always
implemented in practice, even if backed by strong evidence. Mediating factors include health policy and health
system influences, organisational factors, and individual and professional attitudes, including decision makers’
perceptions of innovation evidence. There has been limited research on how different forms of evidence are
accessed and utilised by organisational decision makers during innovation adoption. We also know little about
how diverse healthcare professionals (clinicians, administrators) make sense of evidence and how this collective
sensemaking mediates the uptake of innovations.
Methods: The study will involve nine comparative case study sites of acute care organisations grouped into three
regional clusters across England. Each of the purposefully selected sites represents a variety of trust types and
organisational contexts. We will use qualitative methods, in-depth interviews, observation of key meetings, and
systematic analysis of relevant secondary data to understand the rationale and challenges involved in sourcing and
utilising innovation evidence in the empirical setting of infection prevention and control. We will use theories of
innovation adoption and sensemaking in organisations to interpret the data. The research will provide lessons for
the uptake and continuous use of innovations in the English and international health systems.
Discussion: Unlike most innovation studies, which involve single-level analysis, our study will explore the
innovation-adoption process at multiple embedded levels: micro (individual), meso (organisational), and macro
(interorganisational). By comparing and contrasting across the nine sites, each with different organisational
contexts, local networks, leadership styles, and different innovations considered for adoption, the findings of the
study will have wide relevance. The research will produce actionable findings responding to the political and
economic need for healthcare organisations to be innovation-ready.
Keywords: Evidence, Sensemaking, Innovation adoption, Infection prevention, Qualitative, National Health Service
(NHS), Hospital, Implementation
* Correspondence: y.kyratsis@imperial.ac.uk
National Centre for Infection Prevention and Management, Faculty of
Medicine, Imperial College London, London, UK




© 2012 Kyratsis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Health service delivery and organisation as well as clinical
practice can be improved through the introduction of
novel interventions whose effectiveness is backed by
sound evidence. However, the uptake and implementa-
tion of innovations in healthcare has often proved chal-
lenging and, in some cases, very slow [1,2]. As a result,
research findings are not always translated into changes
in clinical and managerial practice. This reality also raises
the pressing question of how to spread best practice and
implement promising innovations within complex set-
tings such as the UK’s National Health Service (NHS), a
large, professionalised, and highly politicised organisa-
tion. The study makes a timely contribution given the
recent report Innovation, Health and Wealth by the
Department of Health on accelerating the pace of adop-
tion and diffusion of innovations in the NHS [3].
Our study is theory based and grounded in the practical
experience of healthcare managers to provide answers to
persistent challenges. The study draws on organisational
theory, largely on sensemaking in organisations, and on
innovation theory of change. One of the central questions
in this latter body of literature that aligns with the scope
of our study is as follows: ‘Why do innovations not readily
spread, even if backed by strong evidence?’ There is a
growing body of evidence, including empirical cases in
healthcare, that argues that the adoption of new ideas is a
process far more dynamic and complex than previously
suggested. The classic innovation diffusion model of
change, which has influenced UK healthcare policy in the
last decades, suggests that the adoption of innovations is a
rational and linear process, which is conditioned by the
interaction of perceived (by the adopter) innovation attri-
butes with the characteristics of adopters and influences of
the social system [4]. This early innovation diffusion work
has been criticised, however, for taking a simplistic
rational view of change, ignoring the complexities of the
change process, and also focusing on individuals rather
than organisations. Later work in the same tradition has
partially addressed this criticism by explicitly considering
adoption within organisations [5]. Other innovation and
communication studies have departed from the linear
model of diffusion [4] to offer conceptual notions that are
more dynamic and interactive [6-8]. Building on the latter
model, it is suggested that innovation adoption is a process
that is highly dependent on the multiple interactions
between the innovation, local actors, and complex contex-
tual factors [9-12], including epistemic and social bound-
aries amongst different professional groups [13].
In addition, the nature or definition of ‘evidence’
related to innovation is often ambiguous and contested
[2,14]. Managers make decisions based on experience,
personal expertise, judgment, inference, and advice and
do not passively receive new knowledge even if presented
as scientifically produced and validated. Research-based
knowledge has to be constantly interpreted and reframed
along with the local context and clinical or managerial
priorities, a process that often involves power struggles
among various professional groups [15]. Different profes-
sional and managerial groups may interpret evidence dif-
ferently or may prioritise dissimilar types of evidence
partly as a result of their disparate organisational role,
education, and training during their socialisation to the
profession. We employ a sensemaking perspective to gain
insight to this inter- and intraprofessional level and how
this plays out in innovation adoption and implementation
[16]. This lens pays particular attention to the social con-
struction and coproduction of evidence through the
interaction of a range of diverse professional and man-
agerial groups. Our empirical setting of infection preven-
tion and control comprises a multiprofessional workforce
operating in a volatile environment, with infection out-
breaks coupled with high media and public attention, as
well as regulatory and political influences. This environ-
ment thus provides opportunities to contribute to this
body of literature, which has been useful in explaining
organisational response to critical events in the health-
care setting [17,18].
Our work addresses a significant gap in evidence-based
healthcare implementation literature. We respond to the
call for more sustained interpretive work, which explores
the role and motives of actors and the influence of the
organisational context and the social construction of evi-
dence [19]. Overall, we aim to address issues that perme-
ate many stages of the research innovation pathway and,
more specifically, will investigate processes that relate to
the stages of evaluation, adoption, and diffusion. By con-
tributing to the theoretical and empirical discussion, our
study will add to the current international and NHS
policy and practice body of knowledge. Our work also
complements recent and ongoing research commissioned
by the National Institute for Health Research Service
Delivery & Organisation (NIHR SDO) programme; in
particular, it fits well the NIHR SDO 2008 call for propo-
sals that also focused on issues of knowledge utilisation
in healthcare management [20]. We complement and
add to this work by looking at different types of decisions
in different healthcare settings.
Aims and research questions
The study aims to investigate how healthcare managers
draw upon and make sense of different types and sources
of evidence when they make decisions about innovations.
We include general managers and ‘hybrid managers’ (clini-
cians in a managerial role). Special attention is placed on
the role of scientifically produced knowledge and its use
by these managers during the decision-making process
under conditions of innovation uncertainty. The study
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design incorporates multiple levels of analysis as follows:
(a) to explore the influences of wider ‘macro’ level contex-
tual dynamics on managers’ decision making, (b) to
explore decision-making processes at the ‘meso’ organisa-
tional level, (c) to analyse at a ‘micro’ level the processes
by which healthcare managers construct meaning of avail-
able evidence and how they might use such evidence
when deciding on the adoption or rejection of innovations.
Our key research questions are as follows
• How do managers make sense of evidence?
• What role does evidence play in management deci-
sion making when adopting and implementing innova-
tions in healthcare?
• How do wider contextual conditions and intra-orga-
nisational capacity influence research use and applica-
tion by healthcare managers?
Methods
Study design
The study aims to build theory inductively from multiple
in-depth case studies combining inductive search with
deductive reason [21,22]. The selection of cases involved
theoretical, rather than random, sampling [23]. Nine
acute NHS Trusts have been selected across three broad
geographic regions in England (Figure 1). Our selected
NHS Trusts are equally distributed in three regional clus-
ters: (a) London, (b) Northern and Central England, (c)
Southern England. The nine research case studies will be
conducted concurrently. By focusing across different
localities, we aim to explore the influence of any local
network effects if present, for instance, by comparing
London-based institutions to non-London-based institu-
tions–bearing in mind the fact that London is a major
cosmopolitan city with many healthcare institutions, uni-
versities, and research centres, and with a plethora of
social and professional events taking place on a regular
basis. We anticipate that this potential ‘regional effect’
may exert influence on the behaviour and perceptions of
academics, health professionals, and managers.
In our sample of cases, we include examples of research-
engaged healthcare organisations, such as academic health
science centres (AHSC) and university/teaching hospitals,
and ‘ordinary’ healthcare service providers, such as district
general hospitals. To better delineate the impact of con-
textual factors in research use and application by health-
care managers on the adoption and implementation of the
same innovation, we include multiple ‘showcase hospitals’
(as selected by the Department of Health to evaluate the
in-use value of healthcare-associated, infection-related
technologies).
The study will be conducted in two phases, looking in
detail at processes in context, first at espoused use of evi-
dence and then evidence use in practice at point of
decisions. Phase 1 explores perceptions of senior and
operational managers and health professionals in man-
agerial roles across each trust and, specifically, in infec-
tion control. Phase 2 explores those organisational
members involved in the adoption decisions and imple-
mentation of particular technologies in infection preven-
tion and control. We sample for three technologies in
each trust fulfilling the following criteria: (a) currently
being considered for adoption, (b) successfully adopted
and implemented, (c) rejected or discontinued after
initial adoption. Using a systematic options appraisal, we
will bound the technology by infection prevention con-
trol priority area (including hand hygiene, diagnostics,
environmental hygiene/cleaning/disinfection, antibiotic
prescribing, catheter-related care, training and education,
medical devices/equipment hygiene, information technol-
ogy surveillance systems, patient hygiene) and time frame
(of adoption). Technologies considered in the realm of
infection prevention and control prior to 2007 will not be
included to avoid recall bias and incomplete data due to
staff turnover.
Data collection
The study will last two years and data collection will be
longitudinal. Detailed templates will be developed to cap-
ture and summarise secondary sources of data and
important contextual influences for each of the partici-
pating hospitals. This will capture the historical dimen-
sion and ‘hard’ (hierarchy, performance, incentives,
control) and ‘soft’ (espoused values and vision) aspects of
organisational culture.
Primary data will comprise semistructured research
interviews and research field notes. Some respondents will
be interviewed more than once if their organisational role
overlaps phase 1 and phase 2 samples. Hence some of the
research participants will be involved in the study for two
years. Semistructured interview schedules, including short
questionnaires with a more structured format, will be
developed for the two phases of primary data collection
(Additional file 1: Interview Schedule for Phase 1, Addi-
tional file 2: Interview Schedule for Phase 2). All data-
collection tools will be qualitative in nature and piloted
prior to application. The interview accounts will be audio
recorded once consent is given by participants.
Informants will include senior, middle, and operational
managers; representatives from different professional
groups, including medical doctors, infection control spe-
cialists, pharmacists, clinical microbiologists, nurses, and
allied health professionals; patient representative groups;
and nonclinical managers and senior administrators
Table 1.
Primary data collection will also include observation of
key events. Events sampling will focus on technologies
currently being considered for adoption in participating
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trusts to allow ‘real-time’ decision-making processes to
be explored. Potential events may include infection con-
trol team meetings, procurement action group meetings,
and trust-based presentation events for new
technologies.
Total number of interviews will vary according to the
size of the trust and type and span of the innovation. A
minimum sample of 6 to 10 key informants per trust is
planned, with follow-up interviews and further snowbal-
ling to address gaps in the emerging ‘story’. Hence, it is
estimated that a minimum of 90 to 100 informants will be
interviewed overall. The scheduling of interviews over the
two-year study will allow opportunities for further snow-
balling and follow-up interviews with the same respon-
dents where appropriate.
Data analysis
Soon after the completion of interviews, the content of
audio recordings will be transcribed verbatim. Upon
completion of transcription, at least three researchers
will thoroughly read through the full transcribed text sev-
eral times to enable understanding of the meaning of
data in its entirety [24]. The qualitative data analysis
computer software package NVivo 9 (QSR International,
Cambridge, MA, USA) will be used to systematically
code the collected data and assist analysis. In line with
recommendations by qualitative methodologists, we will
use multiple coders to enhance interrater reliability of
the qualitative study [24,25].
Our qualitative analysis will follow an integrated
approach [26]. We will employ an inductive approach to
open up new lines of enquiry and then agree on a frame-
work for data analysis based on these findings together
with our theoretical framework (delineating factors that
influence the adoption process of complex health innova-
tions) and our previous work in 12 NHS Trusts looking at
adoption and implementation processes for new technolo-
gies [27]. Hence, we will employ both an ‘inductive and
Figure 1 Field investigation plan: characteristics of sites and sampling of potential informants in each trust.
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ground-up’ development of codes, as well as a ‘deductive
organising framework as a start-up list’ [26].
Based on the typology suggested by Bradley et al. ([26]
p1763), the code types employed in the study are as
follows:
(a) Conceptual codes and subcodes: to identify key
concept domains and essential dimensions of these
domains
(b) Relationship codes: to identify links between other
concepts coded with conceptual codes
(c) Participant perspective codes: to identify whether
the participant was positive, negative, or indifferent in
attitude about a particular experience or part of an
experience
(d) Participant characteristic codes: based on profes-
sional/occupational group, hierarchical position, func-
tional role
(e) Setting codes: including rural urban setting, hospi-
tal site, particular geographic region, type of trust, Stra-
tegic Health Authority
The development of the code structure will be fina-
lised when theoretical saturation is achieved in each of
the empirical cases [28,29].
Analysis within cases will be followed by the cross-case
analysis across emergent themes but also against the
more formal organisational ‘type’ used in our purposeful
sampling of sites. Individual case study reports with com-
mon formats will be produced as an additional research
output for each of the nine trusts. Summary tables will
be used to simultaneously compare several categories
and dimensions of the content and context of change
implied by the adoption and implementation of the inno-
vations across the nine trusts. Pairs of cases as well as
groups will be compared by listing similarities and differ-
ences in processes, experiences, and outcomes [21].
Discussion
Our approach allows the application of interpretive
methods of inquiry without abandoning the commitment
to arrive at a plausible account of commonly shared
‘objective’ reality. Whilst we uphold that the world and
reality do exist independently of the observer, it is not
possible for the researcher to escape the social world in
order to study the empirical reality [30]. Any given reality
can be represented from a range of different perspectives,
each perspective being potentially true. This stance pre-
sents a possibility of multiple, valid descriptions of the
same social phenomenon. We emphasise a more inter-
pretive stance to explore why different understandings
and meanings emerge for one observation, and how this
explains different views of ‘scientific’ evidence and when
and how different sources of evidence come into play. In
addition, we investigate how negotiated orders within
teams and organisations validate perceptions and hence
lead to sometimes ‘hierarchical’ views of different sources
of evidence.
The potential for learning and generation of new knowl-
edge from this in-depth qualitative study is substantial due
Table 1 Sampling of informants, phase 1
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to the policy-relevant research aims and fit with methodo-
logical approach. We employ a study design of compara-
tive case studies and involve multiple methods, namely,
in-depth semistructured interviews, observation of key
meetings, short survey questionnaires incorporated in the
interviews’ topic guide, reflective field notes, and systema-
tic collection and analysis of relevant secondary data from
within and outside of the organisations studied. The study
is grounded in organisation and management theory, thus
enhancing the generalisibility of the findings. We incorpo-
rate multilevel analysis exploring influences at micro (indi-
vidual), meso (organisation/organisational unit), and
macro (wider context beyond the organisation) levels and
interlevel interactions. Bounding our study in the empiri-
cal setting of infection prevention and control facilitates
this multilevel analysis. In addition, by employing comple-
mentary theoretical approaches, we will triangulate our
findings. We will be able to explain how sensemaking
occurs when multiple stakeholder groups are involved and
the ways in which accounts they generate are–or are not–
reconciled [31]. We will situate this within the meso and
macro contexts to allow generalisability of our findings.
By combining retrospective and ongoing data, we will
explore the social and organisational influences on how
evidence is constructed and becomes meaningful to
diverse organisational actors. This will allow us to develop
a better understanding than short-term and ‘snap-shot’
methods. As well as the above measures of methodological
rigour, we will use measures of acceptability and relevance
of the research as defined by key stakeholders, namely,
policy makers, academics, clinicians, health managers, and
patients. Active involvement of academic experts, health
professionals, people with exposure in policy development
within the Department of Health, and members of the
public through steering-group membership will inform
our research. Specifically, our steering-committee mem-
bers will inform the study design, be involved in the man-
agement and oversight of the study, provide feedback on
early findings, assist in dissemination of findings to diverse
localities and forums, and (through public involvement)
advise on ‘plain English’ summaries of our research
outputs.
The current climate of policy and financial uncertainty
does pose a challenge in getting access to trusts and
informants. We have planned recruitment acknowled-
ging this, and contingency plans have been in place (i.e.,
we determined an additional pool of potential trusts to
replace all types of hospitals initially targeted). We are
also mindful of potential challenges in securing inter-
views over the winter months due to seasonal pressures
on hospital staff and the further potential adverse
impact of infection outbreaks. We are also aware of the
challenges that may arise in coordinating and complet-
ing ethical review by NHS sites (completing global and
local governance checks across all nine trusts and
obtaining letters of access) in time to start data collec-
tion as planned. Finally, due to the inductive nature of
the study, the number of interviews may vary depending
on analytic saturation as well as the nature of technolo-
gies sampled. On limitations, a qualitative process study
may span a longer duration (greater than 18 months in
the field); however, such a project may have posed a
higher risk with diminishing returns on research invest-
ment given the empirical setting as described above. We
do have a longer retrospective dimension in four of the
trusts as they comprised a sample from our previous
study, which looked at the adoption and implementation
processes of novel technologies [27].
Additional material
Additional file 1: Phase 1 Interview Thematic Schedule and
Questions - Managers.
Additional file 2: Phase 2 Interview Thematic Schedule and
Questions - Adopters and Implementers.
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